Exhibit 10.1

Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods:

(a) By completing Items 8 and 15, and returning            copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of
the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment, you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

[CONTINUATION OF BLOCK 14 OF SF 30]

     This Modification No. 0007 to Contract No. HHSO100200500006C (this “Modification”), entered into and made effective as of the date imprinted in Block 16C of the Standard Form 30, is by and between the UNITED STATES OF AMERICA, represented by the Department of Health and Human Services, Biomedical Advanced Research and Development Authority (the “Government” or “USG”), and HUMAN GENOME SCIENCES, INC., a Delaware company, with a principal place of business located at 14200 Shady Grove Road, Rockville, Maryland 20850 (“HGS” or the “Contractor”) (USG and HGS hereinafter each being referred to as a “Party,” and collectively being referred to as the “Parties”), who jointly agree to be bound by the terms and conditions hereof,

     WITNESSETH THAT,

     WHEREAS, HGS is a biopharmaceutical company that produces Raxibacumab (ABthrax™), which is a human monoclonal antibody that specifically targets and blocks Bacillus anthracis protective antigen; and

     WHEREAS, USG desires to purchase and stockpile therapeutic products to treat persons with inhalational anthrax disease; and

     WHEREAS, USG desires to maintain manufacturing facilities for anthrax therapeutic products in compliance with current Good Manufacturing Practices; and

     WHEREAS, USG and HGS are Parties to an existing contract, which contract is identified in Block 10 of the Standard Form 30 (the “Contract”), originally awarded on 23 September 2005 for the purposes of supplying the Strategic National Stockpile (“SNS”) with a therapeutic product to treat inhalational anthrax disease; and

     WHEREAS, HGS delivered 20,001 doses of Raxibacumab (ABthrax™) to the SNS between 29 January 2009 and 5 May 2009 in satisfaction of the quantity theretofore ordered under Contract Line Item Number (CLIN) 0003A; and

     WHEREAS, HGS submitted a Biologics License Application on 13 May 2009 to the Center for Drug Evaluation and Research in the Food and Drug Administration for the purposes of requesting permission to introduce Raxibacumab (ABthrax™) into interstate commerce; and

     WHEREAS, USG and HGS wish to modify the Contract to require HGS to furnish additional doses of Raxibacumab (ABthrax™) under such conditions as are more specifically hereinafter set forth.

     NOW, THEREFORE, in consideration of the mutual promises and other good and valuable consideration contained herein, the receipt and sufficiency of which is hereby acknowledged, each Party, intending to be legally bound, hereby agrees as follows:

     1. Contract section B.6 entitled Contract Line Item Numbers (CLINs) is changed by adding the following to the end of the table:

      Definitions : “CLIN” shall mean Contract Line Item Number; “Qty” shall mean Quantity; “U/I” shall mean Unit of Issue; “NTE” shall mean Not-to-Exceed; “NSP” shall mean Not Separately Priced.